Perrigo's PBM Infant Formula Unit Wins Appellate Judgment Versus Mead Johnson
ALLEGAN, Mich., April 21, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that the United States Court of Appeals for the fourth Circuit has affirmed an earlier decision that Mead Johnson had engaged in false advertising resulting in an injunction prohibiting Mead Johnson from making similar claims and awarding damages in favor of PBM.
Perrigo's Chairman and CEO Joseph C. Papa concluded, "We are pleased that the Appeals Court affirmed the District Court's decision in favor of PBM. The Court has made it clear that national brand and store brand suppliers are entitled to fairly compete and advertising abuses will not be tolerated. We also appreciate the Court's recognition that PBM could lawfully compare its products to national brand products."
Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products. The Company is the world's largest store brand manufacturer of OTC pharmaceutical products and infant formulas. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).
Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 26, 2010, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
More by this Source
Perrigo Receives FDA Final Approval For Generic Equivalent To Prandin®
Jan 24, 2014, 07:50 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.